Joe Tiralongo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joe Tiralongo has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Day
Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, Australia
15 shared publications - Mark von Itzstein
Institute for Biomedicine and Glycomics, Griffith University
14 shared publications - Evelin Tiralongo
School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Australia
12 shared publications - Thomas Haselhorst
Institute for Biomedicine and Glycomics, Gold Coast Campus, Griffith University Southport Queensland Australia
11 shared publications Rita Gerardy-Schahn
9 shared publicationsLauren E. Hartley-Tassell
Institute for Glycomics, Griffith University, Southport 4222, Queensland Australia
7 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in SSRN Electronic Journal
Silane Self-Assembled Monolayers for High-Sensitivity, Ultra-Thin Surface Plasmon Resonance Biosensing
Recent advances in surface plasmon resonance (SPR) technology have enabled real-time, label-free detection of biomolecular interactions with exceptional sensitivity. However, the most common immobilization strategy using carboxymethyl dextran hydrogel matrices, can introduce steric hindrance, non-specific interactions, and decreased signal sensitivity due to their substantial thickness. The development of thinner, more uniform, and chemically versatile coatings remains essential for improving the performance of SPR-based biosensors. Herein, we investigate the use of chemical vapor deposition (CVD) of 3-(glycidyloxypropyl)trimethoxysilane (GOPTS) and 3-(triethoxysilyl)propyl isocyanate (TEPI) to generate self-assembled monolayers (SAMs) for covalent biofunctionalization of gold SPR sensor surfaces. Silane SAMs provide closer proximity of biomolecular binding sites to the plasmonic surface, enhancing assay sensitivity while eliminating the need for additional coupling agents through their inherent epoxide or isocynate reactivity. Using β2-microglobulin as a model analyte, we demonstrate that silane SAMs-modified SPR chips exhibit superior analyte sensitivity and stability compared to commercial SPR chips. These findings establish silane SAMs deposited via CVD as a robust, cost-effective, and reproducible biofunctionalization strategy for SPR systems, offering a framework that can be extended to other label-free detection platforms. More broadly, this approach provides a pathway toward next generation miniaturized and high-resolution biosensing technologies.
- 24 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSilane Self-Assembled Monolayers for High-Sensitivity, Ultra-Thin Surface Plasmon Resonance Biosensing
Recent advances in surface plasmon resonance (SPR) technology have enabled real-time, label-free detection of biomolecular interactions with exceptional sensitivity. However, the most common immobilization strategy using carboxymethyl dextran hydrogel matrices, can introduce steric hindrance, non-specific interactions, and decreased signal sensitivity due to their substantial thickness. The development of thinner, more uniform, and chemically versatile coatings remains essential for improving the performance of SPR-based biosensors. Herein, we investigate the use of chemical vapor deposition (CVD) of 3-(glycidyloxypropyl)trimethoxysilane (GOPTS) and 3-(triethoxysilyl)propyl isocyanate (TEPI) to generate self-assembled monolayers (SAMs) for covalent biofunctionalization of gold SPR sensor surfaces. Silane SAMs provide closer proximity of biomolecular binding sites to the plasmonic surface, enhancing assay sensitivity while eliminating the need for additional coupling agents through their inherent epoxide or isocynate reactivity. Using β2-microglobulin as a model analyte, we demonstrate that silane SAMs-modified SPR chips exhibit superior analyte sensitivity and stability compared to commercial SPR chips. These findings establish silane SAMs deposited via CVD as a robust, cost-effective, and reproducible biofunctionalization strategy for SPR systems, offering a framework that can be extended to other label-free detection platforms. More broadly, this approach provides a pathway toward next generation miniaturized and high-resolution biosensing technologies.
- Open Access
- 22 September 2025
- Published by Elsevier in Food Chemistry
- Vol. 495 (Pt 2) , 146468
Mushroom β-glucans as immunomodulators: Elucidation of structure-function relationship
- 22 September 2025
- Published by Elsevier in Food Chemistry
- Vol. 495 (Pt 2) , 146468
Open AccessMushroom β-glucans as immunomodulators: Elucidation of structure-function relationship
- Open Access
Mushroom Natural Products in Neurodegenerative Disease Drug Discovery
The variety of drugs available to treat neurodegenerative diseases is limited. Most of these drug’s efficacy is restricted by individual genetics and disease stages and usually do not prevent neurodegeneration acting long after irreversible damage has already occurred. Thus, drugs targeting the molecular mechanisms underlying subsequent neurodegeneration have the potential to negate symptom manifestation and subsequent neurodegeneration. Neuroinflammation is a common feature of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis, and is associated with the activation of the NLRP3 inflammasome, which in turn leads to neurodegeneration. Inflammasome activation and oligomerisation is suggested to be a major driver of disease progression occurring in microglia. With several natural products and natural product derivatives currently in clinical trials, mushrooms have been highlighted as a rich and largely untapped source of biologically active compounds in both in vitro and in vivo neurodegenerative disease models, partially supported by successful clinical trial evaluations. Additionally, novel high-throughput methods for the screening of natural product compound libraries are being developed to help accelerate the neurodegenerative disease drug discovery process, targeting neuroinflammation. However, the breadth of research relating to mushroom natural product high-throughput screening is limited, providing an exciting opportunity for further detailed investigations.
Open AccessMushroom Natural Products in Neurodegenerative Disease Drug Discovery
The variety of drugs available to treat neurodegenerative diseases is limited. Most of these drug’s efficacy is restricted by individual genetics and disease stages and usually do not prevent neurodegeneration acting long after irreversible damage has already occurred. Thus, drugs targeting the molecular mechanisms underlying subsequent neurodegeneration have the potential to negate symptom manifestation and subsequent neurodegeneration. Neuroinflammation is a common feature of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis, and is associated with the activation of the NLRP3 inflammasome, which in turn leads to neurodegeneration. Inflammasome activation and oligomerisation is suggested to be a major driver of disease progression occurring in microglia. With several natural products and natural product derivatives currently in clinical trials, mushrooms have been highlighted as a rich and largely untapped source of biologically active compounds in both in vitro and in vivo neurodegenerative disease models, partially supported by successful clinical trial evaluations. Additionally, novel high-throughput methods for the screening of natural product compound libraries are being developed to help accelerate the neurodegenerative disease drug discovery process, targeting neuroinflammation. However, the breadth of research relating to mushroom natural product high-throughput screening is limited, providing an exciting opportunity for further detailed investigations.
- Open Access
- 3 November 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 4 (24) , 5355-5364
Sugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptors
Interactions between sialic acid (Sia) and sialic acid-binding immunoglobulin-like lectins (siglecs) regulate the immune system, with aberrations contributing to pathologies such as autoimmunity, infectious disease and cancer. Over the last decade, several multivalent Sia ligands have been synthesized to modulate the Sia-binding affinity of proteins/lectins. Here, we report a novel class of multivalent siglec probes through the decoration of α(2,6)-sialyllactose ligands on inherently fluorescent carbon dots (CD). We show that the preference of α(2,3)-linked Sia for siglec-1 can be altered by increasing the multivalence of Sia ligands present on the CD, and that a locally high glycan concentration can have a direct effect on linkage specificity. Additionally, micromolar (IC50 ∼ 70 μM) interaction of α(2,6)-sialyllactose-CD (6-CD) with siglec-2 (CD22) revealed it was capable of generating a significant cytotoxic effect on Burkitt's Lymphoma (BL) Daudi B cells. This phenonomen was attributed to 6-CD's ability to form trans interactions with CD22 on masked BL Daudi cells as a direct result of clustering of the Sia moiety on the CD surface. Overall, our glycoengineered carbon dots represent a novel high affinity molecular probe with multiple applications in sialoglycoscience and medicine.
- 3 November 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 4 (24) , 5355-5364
Open AccessSugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptors
Interactions between sialic acid (Sia) and sialic acid-binding immunoglobulin-like lectins (siglecs) regulate the immune system, with aberrations contributing to pathologies such as autoimmunity, infectious disease and cancer. Over the last decade, several multivalent Sia ligands have been synthesized to modulate the Sia-binding affinity of proteins/lectins. Here, we report a novel class of multivalent siglec probes through the decoration of α(2,6)-sialyllactose ligands on inherently fluorescent carbon dots (CD). We show that the preference of α(2,3)-linked Sia for siglec-1 can be altered by increasing the multivalence of Sia ligands present on the CD, and that a locally high glycan concentration can have a direct effect on linkage specificity. Additionally, micromolar (IC50 ∼ 70 μM) interaction of α(2,6)-sialyllactose-CD (6-CD) with siglec-2 (CD22) revealed it was capable of generating a significant cytotoxic effect on Burkitt's Lymphoma (BL) Daudi B cells. This phenonomen was attributed to 6-CD's ability to form trans interactions with CD22 on masked BL Daudi cells as a direct result of clustering of the Sia moiety on the CD surface. Overall, our glycoengineered carbon dots represent a novel high affinity molecular probe with multiple applications in sialoglycoscience and medicine.
- 19 February 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 205, 114088
Picomolar detection of carbohydrate-lectin interactions on piezoelectrically printed microcantilever array
- 19 February 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 205, 114088
Picomolar detection of carbohydrate-lectin interactions on piezoelectrically printed microcantilever array
- 25 June 2021
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 7 (8) , 2383-2389
Identification of the Glycan Binding Profile of Human and Rodent Plasmodium Sporozoites
The transmission of Plasmodium spp. sporozoites to the mammalian host is the first step in the initiation of the mosquito-borne disease known as malaria. The exact route of transmission from the bloodstream to the liver is still not clearly elucidated, and identification of the host glycan structures bound by the sporozoites may inform as to which host cells are involved. Here, we provide a comprehensive analysis of the glycan structures that sporozoites from the human pathogen, P. falciparum, and the rodent pathogen, P. yoelii, recognize and bind. Glycan array analysis was used to profile the glycans bound by the sporozoites, and the binding affinities of these sporozoite-glycan interactions were then determined by surface plasmon resonance. Data showed that the different Plasmodium spp. bind different classes of glycans. P. falciparum was observed to bind to glycans with terminal N-acetylgalactosamine (GalNAc) or Galactose (Gal) linked to a GalNAc, and the highest-affinity observed was with the GalNAc monosaccharide (12.5 nM). P. yoelii bound glycosaminoglycans, mannosyl glycans, Gal linked to N-acetylglucosamine structures, and the αGal epitope. The highest-affinity interaction for P. yoelii was with the αGal epitope (31.4 nM). This is the first study to identify the key host glycan structures recognized by human and rodent Plasmodium spp. sporozoites. An understanding of how Plasmodium sporozoites interact with the specific glycan structures identified here may provide further insight into this infectious disease that could help direct the design of an effective therapeutic.
- 25 June 2021
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 7 (8) , 2383-2389
Identification of the Glycan Binding Profile of Human and Rodent Plasmodium Sporozoites
The transmission of Plasmodium spp. sporozoites to the mammalian host is the first step in the initiation of the mosquito-borne disease known as malaria. The exact route of transmission from the bloodstream to the liver is still not clearly elucidated, and identification of the host glycan structures bound by the sporozoites may inform as to which host cells are involved. Here, we provide a comprehensive analysis of the glycan structures that sporozoites from the human pathogen, P. falciparum, and the rodent pathogen, P. yoelii, recognize and bind. Glycan array analysis was used to profile the glycans bound by the sporozoites, and the binding affinities of these sporozoite-glycan interactions were then determined by surface plasmon resonance. Data showed that the different Plasmodium spp. bind different classes of glycans. P. falciparum was observed to bind to glycans with terminal N-acetylgalactosamine (GalNAc) or Galactose (Gal) linked to a GalNAc, and the highest-affinity observed was with the GalNAc monosaccharide (12.5 nM). P. yoelii bound glycosaminoglycans, mannosyl glycans, Gal linked to N-acetylglucosamine structures, and the αGal epitope. The highest-affinity interaction for P. yoelii was with the αGal epitope (31.4 nM). This is the first study to identify the key host glycan structures recognized by human and rodent Plasmodium spp. sporozoites. An understanding of how Plasmodium sporozoites interact with the specific glycan structures identified here may provide further insight into this infectious disease that could help direct the design of an effective therapeutic.
- Open Access
Bacteriophage adaptation to a mammalian mucosa reveals a trans-domain evolutionary axis
The majority of viruses within the human gut are obligate bacterial viruses known as bacteriophages (phages) 1 . Their bacteriotropism underscores the study of phage ecology in the gut, where they sustain top-down control 2–4 and co-evolve 5 with gut bacterial communities. Traditionally, these were investigated empirically via in vitro experimental evolution 6–8 and more recently, in vivo models were adopted to account for gut niche effects 4,9 . Here, we probed beyond conventional phage-bacteria co-evolution to investigate the potential evolutionary interactions between phages and the mammalian “host”. To capture the role of the mammalian host, we recapitulated a life-like mammalian gut mucosa using in vitro lab-on-a-chip devices (to wit, the gut-on-a-chip) and showed that the mucosal environment supports stable phage-bacteria co-existence. Next, we experimentally evolved phage populations within the gut-on-a-chip devices and discovered that phages adapt by de novo mutations and genetic recombination. We found that a single mutation in the phage capsid protein Hoc – known to facilitate phage adherence to mucus 10 – caused altered phage binding to fucosylated mucin glycans. We demonstrated that the altered glycan-binding phenotype provided the evolved mutant phage a competitive fitness advantage over their ancestral wildtype phage in the gut-on-a-chip mucosal environment. Collectively, our findings revealed that phages – in addition to their evolutionary relationship with bacteria – are also able to engage in evolution with the mammalian host.
Open AccessBacteriophage adaptation to a mammalian mucosa reveals a trans-domain evolutionary axis
The majority of viruses within the human gut are obligate bacterial viruses known as bacteriophages (phages) 1 . Their bacteriotropism underscores the study of phage ecology in the gut, where they sustain top-down control 2–4 and co-evolve 5 with gut bacterial communities. Traditionally, these were investigated empirically via in vitro experimental evolution 6–8 and more recently, in vivo models were adopted to account for gut niche effects 4,9 . Here, we probed beyond conventional phage-bacteria co-evolution to investigate the potential evolutionary interactions between phages and the mammalian “host”. To capture the role of the mammalian host, we recapitulated a life-like mammalian gut mucosa using in vitro lab-on-a-chip devices (to wit, the gut-on-a-chip) and showed that the mucosal environment supports stable phage-bacteria co-existence. Next, we experimentally evolved phage populations within the gut-on-a-chip devices and discovered that phages adapt by de novo mutations and genetic recombination. We found that a single mutation in the phage capsid protein Hoc – known to facilitate phage adherence to mucus 10 – caused altered phage binding to fucosylated mucin glycans. We demonstrated that the altered glycan-binding phenotype provided the evolved mutant phage a competitive fitness advantage over their ancestral wildtype phage in the gut-on-a-chip mucosal environment. Collectively, our findings revealed that phages – in addition to their evolutionary relationship with bacteria – are also able to engage in evolution with the mammalian host.
- 26 October 2020
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 36 (44) , 13181-13192
Functional Microarray Platform with Self-Assembled Monolayers on 3C-Silicon Carbide
Currently available bioplatforms such as microarrays and surface plasmon resonators are unable to combine high-throughput multiplexing with label-free detection. As such, emerging microelectromechanical systems (MEMS) and microplasmonics platforms offer the potential for high-resolution, high-throughput label-free sensing of biological and chemical analytes. Therefore, the search for materials capable of combining multiplexing and label-free quantitation is of great significance. Recently, interest in silicon carbide (SiC) as a suitable material in numerous biomedical applications has increased due to its well-explored chemical inertness, mechanical strength, bio- and hemocompatibility, and the presence of carbon that enables the transfer-free growth of graphene. SiC is also multifunctional as both a wide-band-gap semiconductor and an efficient low-loss plasmonics material and thus is ideal for augmenting current biotransducers in biosensors. Additionally, the cubic variant, 3C-SiC, is an extremely promising material for MEMS, being a suitable platform for the easy micromachining of microcantilevers, and as such capable of realizing the potential of real time miniaturized multiplexed assays. The generation of an appropriately functionalized and versatile organic monolayer suitable for the immobilization of biomolecules is therefore critical to explore label-free, multiplexed quantitation of biological interactions on SiC. Herein, we address the use of various silane self-assembled monolayers (SAMs) for the covalent functionalization of monocrystalline 3C-SiC films as a novel platform for the generation of functionalized microarray surfaces using high-throughput glycan arrays as the model system. We also demonstrate the ability to robotically print high throughput arrays on free-standing SiC microstructures. The implementation of a SiC-based label-free glycan array will provide a proof of principle that could be extended to the immobilization of other biomolecules in a similar SiC-based array format, thus making potentially significant advances to the way biological interactions are studied.
- 26 October 2020
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 36 (44) , 13181-13192
Functional Microarray Platform with Self-Assembled Monolayers on 3C-Silicon Carbide
Currently available bioplatforms such as microarrays and surface plasmon resonators are unable to combine high-throughput multiplexing with label-free detection. As such, emerging microelectromechanical systems (MEMS) and microplasmonics platforms offer the potential for high-resolution, high-throughput label-free sensing of biological and chemical analytes. Therefore, the search for materials capable of combining multiplexing and label-free quantitation is of great significance. Recently, interest in silicon carbide (SiC) as a suitable material in numerous biomedical applications has increased due to its well-explored chemical inertness, mechanical strength, bio- and hemocompatibility, and the presence of carbon that enables the transfer-free growth of graphene. SiC is also multifunctional as both a wide-band-gap semiconductor and an efficient low-loss plasmonics material and thus is ideal for augmenting current biotransducers in biosensors. Additionally, the cubic variant, 3C-SiC, is an extremely promising material for MEMS, being a suitable platform for the easy micromachining of microcantilevers, and as such capable of realizing the potential of real time miniaturized multiplexed assays. The generation of an appropriately functionalized and versatile organic monolayer suitable for the immobilization of biomolecules is therefore critical to explore label-free, multiplexed quantitation of biological interactions on SiC. Herein, we address the use of various silane self-assembled monolayers (SAMs) for the covalent functionalization of monocrystalline 3C-SiC films as a novel platform for the generation of functionalized microarray surfaces using high-throughput glycan arrays as the model system. We also demonstrate the ability to robotically print high throughput arrays on free-standing SiC microstructures. The implementation of a SiC-based label-free glycan array will provide a proof of principle that could be extended to the immobilization of other biomolecules in a similar SiC-based array format, thus making potentially significant advances to the way biological interactions are studied.
- 13 July 2020
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 3 (8) , 7804-7817
Fluorescent Carbon Dots Functionalized with Self-Assembled Glycan Monolayers for Probing Interactions across the Glyco-Interactome
- 13 July 2020
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 3 (8) , 7804-7817
Fluorescent Carbon Dots Functionalized with Self-Assembled Glycan Monolayers for Probing Interactions across the Glyco-Interactome
- Open Access
- 7 November 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224740
Synergistic immuno-modulatory activity in human macrophages of a medicinal mushroom formulation consisting of Reishi, Shiitake and Maitake
A key characteristic of mushroom polysaccharides that elicit an immunomodulatory response is that they are rich in β-glucans and low in α-glucans. In this study we analysed nine commercially available preparations from three mushroom species, Reishi (Ganoderma lucidum), Shiitake (Lentinula edodes) and Maitake (Grifola frondosa), for β- and α-glucan content. Based on β- and α-glucan content we selected three extracts to combine into a formula and evaluated the ability of the individual extracts and formula to impact on the expression of cytokines IL-1α, IL-6, IL-10 and TNF-α in human macrophages with and without LPS stimulation. The majority of mushroom extracts and the formula were found to be highly potent immuno-stimulators possessing EC50 values lower than 100 μg/mL. Interestingly the mushroom formula had lower EC50 values in TNF-α expression from LPS stimulated macrophages compared to the individual extracts, suggesting a potential synergistic effect of the mushroom formula. A response additivity graph and curve-shift analysis illustrated that indeed the mushroom formula exhibited an immuno-stimulatory synergistic effect on the expression of the majority of cytokines evaluated in both LPS stimulated and non-stimulated human macrophages, with IL-10 having an antagonistic response. This study represents the first report of a synergistic immuno-modulatory response in human macrophages elicited from a mushroom formula rationally derived from β- and α-glucan content.
- 7 November 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224740
Open AccessSynergistic immuno-modulatory activity in human macrophages of a medicinal mushroom formulation consisting of Reishi, Shiitake and Maitake
A key characteristic of mushroom polysaccharides that elicit an immunomodulatory response is that they are rich in β-glucans and low in α-glucans. In this study we analysed nine commercially available preparations from three mushroom species, Reishi (Ganoderma lucidum), Shiitake (Lentinula edodes) and Maitake (Grifola frondosa), for β- and α-glucan content. Based on β- and α-glucan content we selected three extracts to combine into a formula and evaluated the ability of the individual extracts and formula to impact on the expression of cytokines IL-1α, IL-6, IL-10 and TNF-α in human macrophages with and without LPS stimulation. The majority of mushroom extracts and the formula were found to be highly potent immuno-stimulators possessing EC50 values lower than 100 μg/mL. Interestingly the mushroom formula had lower EC50 values in TNF-α expression from LPS stimulated macrophages compared to the individual extracts, suggesting a potential synergistic effect of the mushroom formula. A response additivity graph and curve-shift analysis illustrated that indeed the mushroom formula exhibited an immuno-stimulatory synergistic effect on the expression of the majority of cytokines evaluated in both LPS stimulated and non-stimulated human macrophages, with IL-10 having an antagonistic response. This study represents the first report of a synergistic immuno-modulatory response in human macrophages elicited from a mushroom formula rationally derived from β- and α-glucan content.